US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Implantica publishes Interim Report January – March 2026 (Q1)

Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop®Significant events in the first quarter of 2026 · Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening RefluxStop®’s commercial adoption and reimbursement position within the Italian national healthcare system · Expanded the RefluxStop® Centers of Excellence network in Germany with the addition of Klinikum St. Georg in Leipzig and St. Vincenz Hospital Menden, both InEK reporting hospitals supporting Implantica’s reimbursement strategy through the InEK DRG

Notice of Annual General Meeting of Implantica AG

The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to be held on Wednesday, June 10, 2026, at 14:00 at Hotel Kommod, Industriering 14, 9491 Ruggell, Liechtenstein.Right to participate and notice Anyone wishing to attend the annual general meeting must: · be entered as depository receipt holder in the Swedish Depository Receipt (“SDR”) register kept by the Swedish central securities depository Euroclear Sweden on Tuesday, May 26, 2026, and · notify the company of their intention to attend no later

Implantica announces publication of a new health economics study showing RefluxStop®’s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a new RefluxStop® study showing the next-gen surgical solution for GERD is highly cost-effective compared to current standard of GERD care in the Italian healthcare system.The study titled, “Cost-effectiveness of RefluxStop for gastroesophageal reflux disease: analysis from an Italian healthcare perspective” 

Implantica submits final response to FDA in the PMA application for RefluxStop® for U.S. market approval

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that it has submitted its final response to the U.S. Food and Drug Administration (FDA) feedback regarding Module 3 of the Premarket Approval (PMA) application for RefluxStop®.The submission includes Implantica’s responses to FDA’s remaining questions and requests, including the completion of additional testing requested by the Agency following the

Implantica announces new breakthrough long-term RefluxStop® data on severe sufferers presented at DDW 2026

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces breakthrough long-term data from Inselspital in Bern, the largest university hospital in Switzerland, demonstrating excellent safety and efficacy in complex patients, including aperistalsis and lung transplant recipients.Dr. med. Yves Borbély of the Department of Visceral Surgery and Medicine at Inselspital, Bern University Hospital, Switzerland,

RefluxStop® gains momentum at DDW 2026

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces great interest in the RefluxStop® procedure’s unique mechanism of action and excellent clinical outcomes at Digestive Disease Week (DDW) 2026 in Chicago.Independent surgeon, Dr. med. Yves Borbély of the Department of Visceral Surgery and Medicine, Inselspital Bern, Switzerland, a pioneer RefluxStop® surgeon, reported his excellent long-term safety and

Implantica presents the first quarter (Q1 2026) on May 22 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the first quarter 2026 at 15:00 CET on May 22. The interim report for the first quarter (Q1 2026) will be published at 8:00 a.m. CET on the same day.The presentation will be in English via webcast with teleconference: If you wish to participate via webcast, please use the following link: · https://implantica.events.inderes.com/q1-report-2026 If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the

Implantica publishes Annual Report 2025

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2025. The annual report is now available on the company’s website.“Implantica is approaching a potentially defining moment with the FDA PMA process, while at the same time standing on a firm foundation of long-term clinical evidence, real-world validation, cost-effectiveness support, and operational launch readiness. Our priority remains clear: to execute a successful U.S. launch, pending FDA approval, while continuing to scale

Implantica announces landmark RefluxStop[® ]study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature’s Scientific Reports

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux – a condition affecting over 1 billion people worldwide – announces the publication of the largest and first-of-its-kind real-world safety outcomes study of RefluxStop®. The study demonstrating excellent long-term results has been published in Scientific Reports, part of the prestigious Nature portfolio of journals.The study, “Safety outcomes in 602 GERD patients treated by RefluxStop: a multi-center real-

Implantica publishes Year-end Report, January – December 2025 (Q4)

RefluxStop® US Launch Coming Closer, pending FDA approvalSignificant events in the fourth quarter · FDA completed six pre-approval inspections during the quarter – including manufacturing sites, Quality System and BIMO inspections (clinical trial) – all successfully concluded without major findings, as reported in the closing meetings, marking a significant milestone in the PMA review process. · FDA reviewed and provided feedback on our questions related to FDA’s feedback on all three modules of our PMA in the 100-day meeting, and as per Implantica’s review, the final steps to FDA

Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report (Q4 2025) will be published at 8:00 a.m. CET on the same day.The presentation will be in English via webcast with teleconference: If you wish to participate via webcast, please use the following link: · https://implantica.events.inderes.com/q4-report-2025 If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. ·

Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop®

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces over €1.2 million public healthcare funding from two new multi-year public tender approvals in Italy for its groundbreaking acid reflux procedure, RefluxStop®.The new public tender approvals were granted at the Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone” in Palermo and the Ospedale di Brunico (Azienda Sanitaria dell’Alto Adige) in

Implantica strengthens market expansion as Italy’s leading Careggi University Hospital in Florence introduces RefluxStop®

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces adoption of RefluxStop at the world-renowned Careggi University Hospital.The first RefluxStop® procedure at Careggi University Hospital was successfully performed by Dr. Paolo Prosperi, Chief of Emergency Surgery, assisted by Dr. Alessio Giordano. As part of the prestigious University of Florence, Careggi University Hospital is one of Italy’s most

RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons

Implantica AG (publ), a medtech company at the forefront of introducing advanced technology into the body, announced today that its innovative device, RefluxStop®, was a central highlight of the recent Japan Foregut Conference. The exclusive event, organized by Dr. Yasuhiro Fujiwara of the Department of Gastroenterology at Osaka Municipal University, brought together approximately 120 top surgeons and GI experts focusing on cutting-edge foregut disease treatments.The conference provided a key platform for the presentation of compelling long-term clinical evidence for the RefluxStop®

RefluxStop® takes center stage at 2025 European Foregut Society meeting

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces RefluxStop® was a great success at the European Foregut Society (EFS) Annual Meeting in Athens last week.The EFS Annual Meeting, brought together hundreds of Europe’s most highly esteemed acid reflux surgeons, gastroenterologists, and researchers to exchange cutting-edge knowledge on the treatment of foregut diseases. Enthusiasm about RefluxStop® was palpable

Implantica publishes Interim Report January – September 2025 (Q3)

RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market EntrySignificant events in the third quarter of 2025 · Received positive feedback from the FDA on the final PMA Module 3 submission · Expanded production by 10,000 RefluxStop® units, ensuring readiness for rapid U.S. scale-up following FDA approval · Built two new production tools, including one located in the U.S. to support local manufacturing · RefluxStop® generated exceptional enthusiasm at the 2025 American Foregut Society (AFS) Annual Meeting · Hosted a standing-room only clinical panel of leading

Implantica presents the third quarter 2025 on October 31 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.The presentation will be in English via a webcast with teleconference: If you wish to participate via webcast, please use the following link: · https://implantica.events.inderes.com/q3-report-2025       If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces the successful completion of its 100-Day meeting with the U.S. Food and Drug Administration (FDA) regarding the Premarket Approval (PMA) application for RefluxStop®.The 100-Day meeting represents a key milestone in the FDA’s PMA review process, providing an opportunity for the company and the FDA review team to discuss preliminary findings of the

Implantica Successfully Completes MDSAP Recertification Audit

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces the successful completion of its Medical Device Single Audit Program (MDSAP) recertification audit, renewing certifications for Europe, the United States, Canada and Brazil.The audit was conducted last week by Implantica’s notified body, BSI, reaffirming the company’s commitment to maintaining the highest international standards in quality management

Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces its commitment to expand the availability of RefluxStop and training of new centers across Europe and the UK in view of the recent announcement to withdraw the LINX™[1] Reflux Management System[ ]from the European market effective March 31, 2026, as reported across many media outlets.Dr. Peter Forsell, Implantica’s founder, CEO, and the inventor of RefluxStop®,

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the U.S. Food and Drug Administration (FDA) has supplied its review of the final PMA Module 3 submission for RefluxStop® and provided favorable feedback, as assessed by the company.Dr. Peter Forsell, Implantica’s founder, CEO, and the inventor of RefluxStop®, commented: "FDA has now provided its feedback on the final module of our PMA submission for U.S.

Implantica’s RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces RefluxStop® was met with great enthusiasm and positive feedback among 600+ attendees at the 2025 American Foregut Society (AFS) Annual Meeting, further accelerating US pre-launch readiness.Anticipation for RefluxStop® in the US reached a fever pitch last week as the nation’s top foregut surgeons and gastroenterologists gathered in Dallas for the AFS

Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 09 September 2025 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees.A total of 114’931 new SDRS have been created representing a 0.2 % increase in the total number of SDRs. The total number of outstanding SDRs has increased to 58’326’468 post issuance from 58’211’537 pre issuance. The Annual General Meeting held on 10 May 2022 authorized the Board of Directors to execute a Long-Term

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media